Correction: Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients

Lourdes Hontecillas-Prieto; Daniel J. Garcia-Dominguez; Diego Pascual Vaca; Rosa Garcia-Mejias; David Marcilla; Gema L. Ramirez-Villar; Carmen Saez; Enrique de Álava

doi:10.18632/oncotarget.20708

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients

Lourdes Hontecillas-Prieto _, Daniel J. Garcia-Dominguez, Diego Pascual Vaca, Rosa Garcia-Mejias, David Marcilla, Gema L. Ramirez-Villar, Carmen Saez and Enrique de Álava

PDF | How to cite

Oncotarget. 2017; 8:64652-64652. https://doi.org/10.18632/oncotarget.20708

Metrics: PDF 2381 views | ?

Present: The author list is incorrect.

Correct: The proper author list is given below. The authors sincerely apologize for this error.

Original article: Oncotarget. 2017; 8:11173-86. DOI:https://doi.org/10.18632/oncotarget.14491.

Lourdes Hontecillas-Prieto^1,*, Daniel J. Garcia-Dominguez^1,*, Diego Pascual Vaca², Rosa Garcia-Mejias¹, David Marcilla², Gema L. Ramirez-Villar³, Carmen Saez^1,2,#, Enrique de Álava^1,2,#
¹ Institute of Biomedicine of Seville (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, CIBERONC. Seville, Spain
² Pathology Unit, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, CIBERONC. Seville, Spain
³ Pediatric Oncology Unit, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain
^* These authors contributed equally to this work as first authors
^# These authors contributed equally to this work as senior authors

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20708

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients